Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sharper radiation boost aims to tackle head and neck cancers that return

NCT ID NCT02474368

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 1 study tests whether adding a highly targeted, high-dose radiation boost (stereotactic body radiotherapy, or SBRT) to standard radiation and chemotherapy can safely treat head and neck cancer that has come back or spread. The trial includes two groups: patients whose cancer has returned after prior radiation, and those with new tumors in the head and neck from cancer that started elsewhere. The main goal is to find the highest safe dose of the SBRT boost.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of stereotactic body radiotherapy (SBRT), intensity modulated radiation therapy (IMRT), and cisplatin chemotherapy
What this could lead to
If successful, this approach could offer a new treatment option for patients with head and neck cancer that has returned or spread.
What could go wrong
This is an early phase 1 trial with a small number of participants, so the safety and effectiveness are not yet established. The high-dose radiation may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck carcinoma Head and Neck Neoplasms head and neck squamous cell carcinoma metastatic malignant neoplasm nasopharyngeal carcinoma, susceptibility to, 1 salivary gland cancer thyroid cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER METASTATIC HEAD OR NECK CANCER RECURRENT HEAD AND NECK CARCINOMA

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.